期刊文献+

基于释药模型的他克莫司缓释微丸处方设计研究

Application of Drug Release Model in Design of Tacrolimus Sustained-Release Pellets Prescription
原文传递
导出
摘要 目的应用表面降解溶蚀释药模型,指导他克莫司缓释微丸的处方设计,提高设计的准确性和针对性。方法采用单纯形重心设计法,确立处方配比与表面降解速率常数K值的关系,建立起释药模型释放度预测与制剂处方的关联,根据预期的释放度要求,实现对处方设计的指导。并采用热熔包衣技术制备他克莫司缓释微丸,对模型预测和实验测定的释放曲线进行比较。结果测定和预测的释放曲线相似因子f2>75,释放度单点误差<5%。结论本实验所建模型,可根据释放度要求,快速、准确地指导他克莫司缓释微丸的处方设计。 OBJECTIVE To design tacrolimus sustained-release pellets formula by surface degradation and erosion model, and improve the design accuracy and pertinence. METHODS The relationship between the prescription and the surface degradation rate constant K was determined by simplex centroid design. The relationship between dissolution prediction and formulation was established and used to direct the formulation design according to the requirements of the expected dissolution. The dissolution profiles obtained by the model prediction and actual experiment were compared through hot-melt coating technology. RESULTS The dissolution profile similarity factorf2was over 75 between the measured and predicted dissolution profiles, and the single point error of dissolution was be- low 5%. CONCLUSION Using the established model, the formula of tacrolimus sustained-release pellets can be quickly and accu- rately designed according to the dissolution requirement.
出处 《中国药学杂志》 CAS CSCD 北大核心 2015年第21期1888-1892,共5页 Chinese Pharmaceutical Journal
关键词 他克莫司 缓释微丸 释药模型 处方设计 热熔包衣 单纯形重心设计 tacrolimus sustained-release pellet dissolution profile formula design hot-melt coating technology simplex centroid
  • 相关文献

参考文献2

二级参考文献14

  • 1仲静洁,王东凯,张翠霞,高红,张勖.海藻酸钠在药物制剂中的研究进展[J].中国新药杂志,2007,16(8):591-594. 被引量:27
  • 2Kino T, Inamura N, Sakai F, et al. Effect of FK-506 onhuman mixed lymphocyte reaction in vitro. Transplant Proc, 1987, 19(5 suppl 6):S36-39.
  • 3KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J Transplant, 2009, 9 Suppl 3 :S1-155.
  • 4Weng FL, Israni AK, Joffe MM, et al. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. J Am Soc Nephrol, 2005, 16(6) :1839-1848.
  • 5Sudan DL, Shaw BW Jr, Langnas AN. Causes of late mortality in pediatric liver transplant recipients. Ann Surg, 1998, 227(2) :289-295.
  • 6Mecule A, Poli L, Nofroni I, et al. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors. Transplant Proc, 2010, 42 (4) 1317-1119.
  • 7Wlodarczyk Z, Squifflet JP, Ostrowski M, et al. Pharmacokineties for onceversus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open label trial. Am J Transplant, 2009, 9(11) : 2505-2513.
  • 8Abecassis MM, Seifeldin R, Riordan ME. Patient outcomes and economics of once-daily tacrolimus in renal transplant patients: results of a modeling analysis. Transplant Proc, 2008, 40(5) : 1443-1445.
  • 9Florman S. Tacrolimus once-daily formulation in the prophylaxis of transplant rejection in renal or liver allograft recipients: a viewpoint by Sander Flomaan. Drugs, 2007, 67 (13) : 1944.
  • 10盘茂东,李嘉诚,林强,王向辉,汪莉华.海藻酸钠在药物控释中的应用[J].中国药业,2008,17(19):3-5. 被引量:22

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部